I am very happy and honored that i can tell you that our paper “Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study” is the very first paper in the new ISTH journal “Research and Practices in Thrombosis and Hemostasis“.
This new journal, for which I serve on the editorial board, is the sister journal of the JTH, but has a couple of focus point that are not present in the JTH. Biggest difference is the open access policy of the RPTH. Next to that, there are a couple of things or subjects that the RPTH welcomes, which are perhaps not so common in traditional journals (e.g. career development articles, educationals, nursing and patient perspectives etc).
Our paper is however a very standard paper, in the sense that it is original research publication regarding the role of statins and the risk of thrombosis recurrence. We answer the question whether statins indeed is linked with a lower risk of recurrence based on observational data, opening up the door to confounding by indication. To counteract, we applied a propensity score, and most important of all, we only used so-called “incident users”. Incident vs prevalent users of statins is a theme that has been a topic on this blog before (for example here and here). The bottom line is this: people who are currently using statins are different from people who are prescribed statins – adherence issues, side effects, or low life expectancy could be reasons for discontinuation. You need to take this difference between these type of statin users into account, or the protective effect of statins, or any other medication for that matter, might be biassed. In the case of statins and DVT recurrence it can be argued that the risk lowering effect of statins is overestimated. In itself that is not a problem in an observational study. But if the results of this observational study is subsequently used in a sample size calculation for a proper trial, that trial will be underpowered and we might have lost our (expensive and potentially only) shot at really knowing whether or not DVT patients benefit from statins.
RPTH will be launched during ISTH 2017 which will be held in Berlin in a couple of weeks.